35 related articles for article (PubMed ID: 9950195)
1. Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach.
Febvey-Combes O; Guitton J; Marec-Berard P; Faure-Conter C; Blanc E; Chabaud S; Conjard-Duplany A; Schell M; Derain Dubourg L
BMC Pediatr; 2024 Mar; 24(1):196. PubMed ID: 38504218
[TBL] [Abstract][Full Text] [Related]
2. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
Lilienthal I; Herold N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961800
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiological mechanisms underlying a rat model of triple whammy acute kidney injury.
Prieto-García L; Vicente-Vicente L; Blanco-Gozalo V; Hidalgo-Thomas O; García-Macías MC; Kurtz A; Layton AT; Sanz AB; Morales AI; Martínez-Salgado C; Pericacho M; Sancho-Martínez SM; López-Hernández FJ
Lab Invest; 2020 Nov; 100(11):1455-1464. PubMed ID: 32719543
[TBL] [Abstract][Full Text] [Related]
4. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.
Kooijmans EC; Bökenkamp A; Tjahjadi NS; Tettero JM; van Dulmen-den Broeder E; van der Pal HJ; Veening MA
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008944. PubMed ID: 30855726
[TBL] [Abstract][Full Text] [Related]
5. Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.
Jones DP; Spunt SL; Green D; Springate JE;
Pediatr Blood Cancer; 2008 Dec; 51(6):724-31. PubMed ID: 18677764
[TBL] [Abstract][Full Text] [Related]
6. Ethical issues in including pediatric cancer patients in drug development trials.
Aleksa K; Koren G
Paediatr Drugs; 2002; 4(4):257-65. PubMed ID: 11960514
[TBL] [Abstract][Full Text] [Related]
7. Anticancer drug-induced kidney disorders.
Kintzel PE
Drug Saf; 2001 Jan; 24(1):19-38. PubMed ID: 11219485
[TBL] [Abstract][Full Text] [Related]
8. Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature.
Kenney LB; Duffey-Lind E; Ebb D; Sklar CA; Grier H; Diller L
J Pediatr Hematol Oncol; 2014 Apr; 36(3):237-40. PubMed ID: 24667129
[TBL] [Abstract][Full Text] [Related]
9. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
[TBL] [Abstract][Full Text] [Related]
10. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
[TBL] [Abstract][Full Text] [Related]
11. Renal function in children and adolescents following 72 g/m2 of ifosfamide.
Arndt C; Morgenstern B; Wilson D; Liedtke R; Miser J
Cancer Chemother Pharmacol; 1994; 34(5):431-3. PubMed ID: 8070011
[TBL] [Abstract][Full Text] [Related]
12. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
Ferrari S; Pieretti F; Verri E; Tolentinis L; Cesari M; Versari M; Zolezzi C; Lamanna G; Bacci G
Anticancer Drugs; 2005 Aug; 16(7):733-8. PubMed ID: 16027521
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
